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ABSTRACT 
The main intend of the implement sniff out formulate and evaluate oxymetazoline nasal gels. To achieve more persistent blood 
levels with decrease dosage of medicine by extended drug evidence and by passing hepatic initially cross metabolism and body 
including inferable disgrace. The FTIR & DSC spectra there is not any discrepancein the seam clean medicine, polymers & lipids. The 
Carbopol consisting of reinforce precail eventual scintillating moreover transparent Poloxamer, Hydroxy Propyl Methyl cellulose 
gels crop up prospective lucent as a consequence frosted slimy. The pH value of all developed formulations of gels (ONGF1-ONGF8) 
was in the range of 6.2 to 6.9. Spreadability of gels was in the range 19.51 - 33.91 g.cm/sec, The Viscosity of various formulated gels 
was found in range of 8628 to 9622 centipoises. The percentage drug content of all prepared gel formulations were found to be in 
the range of 78.53 to 98.56 %. The gel strength of all prepared formulations of gels was found to be in the range of 69 to 96 %. In-
vitro diffusion drug release of Oxymetazoline Hydrochloride of nasal gels ONGF1 shows the 95% drug release. The release order 
kinetics shows all the formulations ONGF1 to ONGF8 formulations were followed Korsemeyer-Peppas with correlation coefficient 
R2=0.8969 & 0.2692 respectively. ONGF1 formulation follows both Zero order and Korsmeyer-Peppas models, it indicates diffusion 
release mechanism followed by non-fickian transport. 
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INTRODUCTION 
Oxymetazoline hydrochloride (6-tert-Butyl-3-(4,5- 
dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol 
hydrochloride) is an imidazoline derivative 
sympathomimetic amine. Oxymetazoline is a 
vasoconstrictor that acts directly on nasal membranes and 
has been available as a over the counter intranasal drug in 
the United States for more than 40 years 1. It is approved 
for the relief of nasal congestion as a result of common 
colds and allergic rhinitis. The main aim of the present 
work is to formulate and evaluate oxymetazoline nasal gels. 
To achieve more constant blood levels with lower dosage 
of drugs by continuous drug input and by passing hepatic 
first pass metabolism and consequent degradation 2. To 
reduce the frequency of dose dumping and increase the 
residence time. The intranasal administration of drugs has 
long been used for the treatment of rhinitis and nasal 
congestion. Intranasal administration can overcome the 
side effects that happen in the gastrointestinal tract and the 
hepatic first-pass effect 3. Furthermore, drugs are absorbed 
better, because of the abundant blood and lymphatic 
capillaries under the nasal mucosa. Since these properties, 
intranasal administration can effectively enhance the 
bioavailability of drugs. Intranasal administration has been 
stated to reach comparable blood concentrations as 
intravenous administration 4. Most of the commercially 
available nasal preparations are now sprays. The 
scavenging effect of nasal cilia leads to a very short drug 
residence time on the human nasal mucosal surface (only 
15–30 min), which affects the clinical efficacy to some 
extent. The term gel represents a physical state with 
properties intermediate between those of solid and liquids. 
However, it is often wrongly used to describe any fluid 
system that exhibits some degree of rigidity 5. Nasal drug 
delivery also provides a way to the brain that circumvents 
the blood-brain barrier because the olfactory receptor cells 
are in contact with central nervous system directly. The 
first step involved is absorption of drug in the nasal cavity 
is crossing the mucus membrane. Because small, uncharged 
particles can pass through the mucus easily. But charged 
large molecule does not easily passes through the mucus 
membrane. Mucin is the protein present in the mucus layer, 
which binds with the solutes that delays the diffusion and 
structural changes in the mucus layer also possible because 
of environmental changes 6.   
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MATERIALS 
Oxymetazoline hydrochloride were gifted sample from 
Kotra Pharma (M) Sdn Bhd. Poloxamer 188 were 
purchased S.D. Fine Chem. Ltd. Mumbai. 
Hydroxypropylmethyl cellulose procured from Sigma 
Aldrich USA Carbopol procured from Finar Chemicals Ltd, 
Ahmedabad.   All the chemicals were used as HPLC grade. 
METHODOLOGY 
FT-IR studies for drug and excipients compatibilities: 
Prior to the development of the dosage forms the 
preformulation study was carried out 7. IR spectral studies 
lies more in the qualitative identification of substances 
either in pure form or in combination with polymers and 
excipients and acts as a tool in establishment of chemical 
interaction. Since I.R. is related to covalent bonds, the 
spectra can provide detailed information about the 
structure of molecular compounds. In order to establish 
this point, comparisons were made between the spectrum 
of the substances and the pure compound. 
Differential Scanning Calorimetric: Differential Scanning 
Calorimetric of pure drugs and polymers used were studied 
to investigate any changes in melting points of the drug 
after combining it with the excipients 8. Differential 
Scanning Calorimeter curves were obtained by at a heating 
rate of 10°C/min from 25°-250°C in nitrogen atmosphere 
(20 mL/min) with a sample weight of 3mg.  
Formulation of Oxymetazoline Hydrochloride Nasal 
Gels 
Oxymetazoline Hydrochloride Nasal Gels was prepared by 
Dispersion method. In this method weighed quantities of 
polymers such as HPMC K100, Carbopol 934 was dissolved 
in known quantity of distilled water (Solution-A).After 
complete dispersion the polymer solution was kept it aside 
for 24hrs for complete the swelling 9. Accurately weighed 
amount of Oxymetazoline Hydrochloride, Poloxamer 188 
was dissolved in a specified quantity to this solution; 
specified quantity of Phenylmercuric nitrate was added 
and dissolved (Solution-B). Solution A and B were mixed 
thoroughly with the help of high speed magnetic stirrer 
(500rpm) taking precautions that air did not entrap. 
Finally distilled water was added to obtain a homogenous 
dispersion of gel. The pH of the formed gel was adjusted to 
pH 6.8. 
 
Table 1: Formulation data of Oxymetazoline Hydrochloride Nasal gels 
Ingredients  ONGF1  ONGF2 ONGF3  ONGF4  ONGF5  ONGF6  ONGF7  ONGF8  
Oxymetazoline (gms) 1.5  1.5  1.5  1.5 1.5  1.5  1.5  1.5  
Carbopol (gms)  1  1.5  2  2.5  2.5  2  1.5  1  
HPMC (gms)  2.5  2  1.5  1  1  1.5  2  2.5  
Poloxamer  (gms) 0.5  1  1.5  2  0.5  1  1.5  2  
Methyl Paraben (%)  1 1 1 1 1 1 1 1 
Distilled water (ml)  100  100  100  100  100  100  100  100  
 
Evaluation of oxymetazoline nasal gels: Formulated gel 
was evaluated for their clarity, pH, Spreadability, viscosity, 
drug content, Gel strength and in-vitro release studies. 
Clarity: The clarity of various formulations 10 was 
determined by visual inspection under black and white 
background and it was graded as follows; turbid: +, clear: 
++, very clear (glassy): +++.  
Measurement of pH:  The pH of oxymetazoline gel 
formulation was determined by using digital pH meter 
1gram of gel was dissolved in 100ml of distilled water 11. 
The pH of all formulation was determined by using digital 
pH meter. 
Spreadability: It was determined by glass plate apparatus 
which was suitably modified in the laboratory and used for 
the study. Spreadability was measured on the basis of ’slip’ 
and drag characteristics of gel. Spreadability of the 
formulations was determined 48 hrs after preparation, by 
measuring the spreading diameter of 1gm of gel between 
two glass plates after 1 min. the mass of upper plate was 
standardized at 125g. A 1kg weight was placed on the top 
of two slides for 5min to expel air and to provide a uniform 
film of gel between the slides. Excess of gel was scrapped 
off from the edges 12. The top plate was then subjected to 
pull of 80 gm. 
The spredability was measured by using the following 
formula 
  
  
 
 
Where, 
S = Spreadability 
M = Weight tide to upper slide 
L = Length moved on the glass slide 
T = Time taken to separate the slide completely from each 
other 
Viscosity: The viscosity of all gels was measured using a 
brook field viscometer (DV II +). First, the spindle was 
dipped into the gel till the notch on the spindle touched the 
gel surface.100 gm each of formulation gels was used in the 
study 13.  The spindle no. 61 was selected based on the 
viscosity of the gel, this spindle was rotated at 50 rpm, and 
dial reading was recorded until 2 consecutive similar 
readings were obtained.  
Drug content: Drug content of gel was determined by 
dissolving accurately weighed 1 gm gel in 6.8 pH 
Phosphate buffer 14. After suitable dilution absorbance was 
recorded using UV visible spectrometer at 245 nm. Drug 
content was determined using slope of standard curve. The 
drug content was determined by using following equation  
Drug content = (concentration× volume taken) × 
conversion factor 
Gelling strength: In 100 ml measuring cylinder containing 
50 gm of gel at thermostat at 37oC, it allows to penetrate 
into the Carbopol & HPMC gel. At physiological 
temperature while applying pressure on the device sink at 
5cm down, to measure the time in seconds 15.  
In vitro diffusion studies: The in vitro diffusion study of 
prepared gel was carried out in Franz diffusion cell using 
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through an egg membrane. 20 ml of phosphate buffer was 
taken in as receptor compartment, then 5 gm 
Oxymetazoline gel was spreaded uniformly on the 
membrane 16. The donor compartment was kept in contact 
with a receptor compartment and the temperature was 
maintained at 37±0.50C. The solution on the receptor 
pipette out 5 ml of solution from the receptor 
compartment at specified time intervals like 1,  2, 3, 4, 5, 6 
& 7hrs and immediately replaced with the fresh 2 ml 
phosphate buffer. The results of in-vitro release profile 
obtained for all formulations were plotted in Release order 
kinetics as follows:  
Kinetic study the Release Order kinetics Mechanism: 
The results of in-vitro release profile obtained for all 
formulations were plotted in modes 17 of data treatment as 
follows: 
 Cumulative percent drug release V/s. Time (Zero-order).  
 Cumulative percent drug release V/s. Square root of 
Time (Higuchi Matrix Model).  
 Log Cumulative percent drug retained V/s. Time (First-
order).  
 Log Cumulative percent drug release in V/s. log Time 
(Krosmeyer-Peppas Model).  
Zero order kinetics: Drug dissolution from 
pharmaceutical dosage forms that do not disaggregate and 
release the drug slowly, assuming that the area does not 
change and no equilibrium conditions are obtained can be 
represented by the following equation 18 . 
Qt = Qo + Ko t 
Where,  
Qt = Cumulative amount of drug release at time t,  
Qo = Initial amount of drug in the solution  
Ko = zero order release constant 
t = Time in hours 
First order kinetics: To study the first order release 
kinetics the release rate data were fitted to following 
equation 18. 
Log Qt = log Qo + K t / 2.303 
Where, 
Qt= Cumulative amount of drug released at time t,  
Qo = Initial amount of drug in the solution and 
 K= First order release constant. 
Higuchi model: Higuchi developed several theoretical 
models to study the release of water-soluble and low 
soluble drugs incorporated in semisolids and or solid 
matrices 19. Mathematical expressions were obtained for 
drug particles dispersed in a uniform matrix behaving as 
the diffusion media, the equation is 
Q t = KH. t1/2 
Where,  
Q t = Cumulative amount of drug release at time t 
KH = Higuchi dissolution constant 
    t = Time in hours 
Korsemeyer and Peppas Release model: To study this 
model the release rate data are fitted to the following 
equation 20. 
F = Mt / M = K.tn 
 Where, 
F = Fraction of drug released at time‘t’ 
Mt = Amount of drug released at time‘t’ 
M = Total amount of drug in dosage form 
K = Kinetic release constant 
 t = Time in hours and 
 n = Diffusion exponent for the drug release that is 
dependent on the shape of the matrix dosage form.  
A plot of log drug release verses log time will be linear with 
slope of n and intercept gives the value of log K. 
 n = 0.5 indicating pure fickian diffusion. 
 n = 0.5-1 or 0.45-0.89 indicating non fickian diffusion 
ie, the rate of solvent penetration and drug release are 
in the same range. 
 n = 0.89 or 1 indicate zero order release which can be 
achieved when drug diffusion is rapid compared to the 
constant rate of solvent induced relaxation.  
RESULTS AND DISCUSSION 
Compatibility studies 
 
Figure 1:  FTIR spectrum of Oxymetazoline 
Hydrochloride
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Figure 2: FTIR spectra of Carbopol 
 
 
Figure 3: FTIR spectra of Poloxamer 188 
 
 
Figure 4: FTIR spectra of HPMC 
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Figure 5: FTIR spectra of mixture 
 
The drug and polymers were characterized by FTIR 
spectral analysis for any physical as well as chemical 
alteration of the drug characteristics. From the results, it 
was concluded that there was no interference in the 
functional groups as the principle peaks of the 
Oxymetazoline Hydrochloride were found to be unaltered 
in the spectra of the drug-polymer mixture. 
 
Table 2:  FTIR spectrum of observed and characteristic peak of Drug, Lipids, Excipients & Mixture of compounds  
FTIR Spectrum  IR absorption bands (cm-1)  Bond  Functional group  
Observed peak  Characteristic peak  
Oxymetazoline 
Hydrochloride 
2360.95 2100-2660 C=C Alkynes 
2345.52 2100-2660 C=C Alkynes 
1413.87 1330-1540 NO₂  Nitro compounds 
1377.22 1220-1540 NO₂  Nitro compounds 
Carbopol 3363.97 3310-3500 NH 2˚amines 
3084.28 3010-3095 CH Alkene 
2966.62 2500-3000 OH Hydrogen bonded acids 
Poloxamer 188 3602.09 3580-3650 OH Alcohols 
3614.72 3580-3650 OH Alcohols 
2359.02 2100-2660 C=C Alkynes 
2339.73 2100-2660 C=C Alkynes 
2243.29 2240-2275 C=N Iso cyanide 
Hydroxy Propyl Methyl 
cellulose 
3174.94 3000-3300 CH  Alkynes 
3149.86 3000-3300 CH Alkynes 
3051.49 3000-3300 CH Alkynes 
3020.63 3000-3300 CH Alkynes 
1629.90 1620-1680 C=C Alkynes 
Mixture 3244.38 3010-3300 C≡H Alkynes 
2249.07 2100-2660 C=C Alkynes 
2171.92 2100-2660 C=C Alkynes 
2158.42 2100-2660 C=C Alkynes 
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Differential Scanning Calorimetry: 
 
Figure 6: DSC curve of Oxymetazoline 
 
 
Figure 7:  DSC curve of Carbopol 
 
 
Figure 8: DSC curve of HPMC 
 
Figure 9: DSC curve of Poloxamer 
 
Figure 10: DSC curve of Mixture 
 
The oxymetazoline hydrochloride of endothermic peak 
was found to be 194.56oC. The Carbopol of endothermic 
peak was found to be 250oC. The HPMC the endothermic 
peak was found to be 99oC. The Poloxamer of endothermic 
peak was found to be 95oC. The Mixture of endothermic 
peak was found to be 95oC. There is no interaction 
between pure drug, polymer & lipids. As shown in figure 6 
to 10. 
Evaluation of oxymetazoline hydrochloride nasalgels: 
Clarity: Carbopol containing gels were found to be 
sparkling and transparent Poloxamer, Hydroxy Propyl 
Methyl cellulose gels were found to be translucent and 
white viscous. All gels were free from presence of particles 
as shown in Table 3. 
pH: The pH value of all developed formulations of  gels 
(ONGF1-ONGF8) were in the range of 6.2 to 6.9 as shown 
in Table 3. 
Spreadability: The value of spreadability indicates that 
the gel is easily spreadable by small amount of shear. 
Spreadability of gels was in the range 19.51 - 33.91 
g.cm/sec, as shown in Table 3. 
Viscosity measurement: The viscosity of various 
formulated Oxymetazoline Hydrochloride gels was 
measured using a Brookfield viscometer. The rheological 
behavior of all formulated gels systems was studied. In gel 
system, consistency depends on the ratio of solid fraction, 
which produces the structure to liquid fraction. Viscosity of 
various formulated gels was found in range of 8628 to 
9622 centipoises as shown in Table 3. 
Drug content: The percentage drug content of all 
prepared gel formulations were found to be in the range of 
78.53 to 98.56 %. The percentage drug content of 
formulations was found satisfactory. Hence methods 
adopted for gels formulations were found suitable. As 
shown in Table 3. 
Gel strength: The gel strength of all prepared formulations 
of gels was found to be in the range of 69 to 96 %. The 
percentage drug content of formulations was found 
satisfactory. Hence methods adopted for gels formulations 
were found suitable. As shown in Table 3.
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Table 3:  Evaluation parameters of Oxymetazoline nasal gel 
Formulation 
code 
Clarity pH 
Spreadability 
(g.cm/sec) 
Viscosity 
(cps) 
% Drug 
Content 
Gelling 
strength (sec) 
ONGF1 +++ 6.9 21.99 943.2 98.92 65±1 
ONGF2 + 6.8 21.50 962.6 95.53 69±4 
ONGF3 ++ 6.7 26.30 944.2 88.30 70±3 
ONGF4 + 6.7 28.86 855.1 91.56 82±5 
ONGF5 ++ 6.8 18.75 848.9 93.82 68±2 
ONGF6 + 6.7 20.55 871.8 78.02 73±5 
ONGF7 + 7.1 22.39 847.8 83.92 79±3 
ONGF8 + 6.9 18.07 942..2 82.46 96±3 
  
In vitro drug diffusion studies: In vitro drug release studies were carried out on diffusion test apparatus Franz diffusion 
cell. These release studies revealed that, the order of release was found as shown in table 4 & figure 11. 
Table 4: In-vitro diffusion drug release of Oxymetazoline Hydrochloride of nasal gels 
Time 
(Hrs)  
Percentage amount of drug release 
ONGF1 
(%)  
ONGF2 
(%)  
ONGF3  
(%)  
ONGF4  
(%)  
ONGF5  
(%)  
ONGF6  
(%)  
ONGF7  
(%)  
ONGF8 
(%)  
1 42 ± 0.1 48 ± 0.3 40 ± 0.6 32 ±0.4 20 ±0.2  21 ±0.4 22±0.2 19 ±0.1 
2 43 ± 0.4 44 ± 0.6 44 ±0.4 48 ±0.7 34 ± 0.5  37 ±0.6 36 ±0.4 28 ±0.4 
3 47 ± 0.6 52 ± 0.4 58 ±0.2 62 ±0.1 46 ± 0.7 54 ±0.7 48 ±0.5 38 ±0.6 
4 56 ± 0.3 62 ± 0.1  69 ±0.6 64 ±0.2 56 ± 0.6 64 ±0.8 54 ±0.7 46 ±0.5 
5 78 ± 0.2 72 ± 0.6 78 ±0.2  75 ±0.6 72 ±0.1 76 ±0.9 62 ±0.3 58±0.3 
6 79 ± 0.6 83 ± 0.7 87 ±0.7 83 ± 0.3 76 ± 0.2 82±0.3 65 ±0.6 71 ±0.7 
7 95 ± 0.7 93 ± 0.8 94 ±0.3 94 ± 0.1 82 ±0.4 89±0.1 77 ±0.4 84± 0.8 
 
 
 
 
Figure 11: In-vitro drug release Profiles of Formulations ONGF1-ONGF8 
 
Kinetic models data analysis: The results of diffusion 
data fitted to various drug release kinetic equations like 
Zero order, First order, Higuchi model and Korsemeyer-
Peppas. The kinetic values obtained for all formulations 
ONGF1, ONGF2, ONGF3, ONGF4, ONGF5, ONGF6, ONGF7 & 
ONGF8were tabulated respectively, Graphs are Plotted for 
Zero order, First order, Higuchi model and Korsemeyer-
Peppas against cumulative % drug release Vs Time (Hrs), 
Log cumulative % drug remaining Vs Time (Hrs), 
cumulative % drug release Vs Square root of Time, Log 
cumulative % drug release Vs Log Time. 
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Table 6:  In-vitro drug release kinetics data for Formulation ONGF1 
Zero order First order Higuchi’s data Korsmeyer-Peppas data 
Time (h) % CDR Time (h) 
Log % CD 
Remaining 
SQR 
Time 
% CDR Log Time Log % CDR 
0 0 0 2 1 0 0 0 
1 42 1 1.76 1.73 42 0.47 1.62 
2 43 2 1.75 2 43 0.60 1.63 
3 47 3 1.72 2.23 47 0.69 1.67 
4 56 4 1.64 2.44 56 0.77 1.74 
5 78 5 1.34 2.64 78 0.77 1.74 
6 79 6 1.32 2.82 79 0.85 1.89 
7 95 7 0.69 2.82 950 0.90 1.89 
 
Table 7:  Drug Release Kinetics of Oxymetazoline Nasal Gels 
Order Of 
Process 
Zero order First Order Higuchi Korse Meyer 
Peppass 
Mechanism  
R2 slope R2 slope R2 slope R2 n 
ONGF1 0.9056 11.476 0.8278 0.151 0.875 29.806 0.8969 0.823 Non-Fickian 
ONGF2 0.9025 1.1449 0.4821 0.0664 0.7269 39.64 0.6042 0.943 Zeroorder 
ONGF3 0.9262 1.272 0.893 0.0838 0.9215 41.404 0.8592 0.852 Non-Fickian 
ONGF4 0.939 1.386 0.6231 0.0779 0.7635 41.716 0.8095 0.756 Non-Fickian 
ONGF5 0.9648 0.1224 0.971 0.0963 0.9409 47.483 0.9721 0.865 Non-Fickian 
ONGF6 0.9659 0.1607 0.9804 0.1131 0.454 34.502 0.9706 0.831 Non-Fickian 
ONGF7 0.9319 0.201 0.0158 0.0173 0.0103 5.7846 0.3191 0.975 Zero-order 
ONGF8 0.9029 0.2005 0.1054 0.0235 0.0129 4.2484 0.2692 0.853 Non-Fickian 
 
ONGF1, ONGF2, ONGF3, ONGF4, ONGF5, ONGF6, ONGF7 
&ONGF8 formulations were followed Korsemeyer-Peppas 
with correlation coefficient R2=0.8969, 0.6042, 0.8592, 
0.8095, 0.9721, 0.9706, 0.3191& 0.2692 respectively. 
ONGF1 formulation follows both Zero order and 
Korsmeyer-Peppas models, it indicates diffusion release 
mechanism followed by non-fickian transport. 
CONCLUSION  
The present work was carried out to Formulate and 
evaluate oxymetazoline hydrochloride nasal gels was 
prepared by cold method. The FTIR & DSC studies 
confirmed that there is no chemical interaction took place 
during encapsulation process. The Evaluation of 
Oxymetazoline Hydrochloride Nasal Gels performed with 
the clarity test will be transparent. pH value of all 
developed formulations of gels (ONGF1-ONGF8) was in the 
range of 6.2 to 6.9. Spread ability of gels was in the range 
19.51 - 33.91 g.cm/sec. Viscosity of various formulated gels 
was found in range of 8628 to 9622 centipoises. The 
percentage drug content of all prepared gel formulations 
were found to be in the range of 78.53 to 98.56 %. The 
percentage drug content of formulations was found 
satisfactory. The gel strength of all prepared formulations 
of gels was found to be in the range of 69 to 96 %. The In-
vitro release of oxymetazoline HCl was prolonged release 
of drug ranges from 95 % of released within 7 hour. Among 
the eight formulations the best formulation is ONGF 1 
formulation follows both Zero order and Korsemeyer-
Peppas models, It indicates diffusion release mechanism 
followed by non-fickian transport. 
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